More general and universally applicable drug discovery assay technologies are needed in order to keep pace with the recent advances in combinatorial chemistry and genomics-based target generation. Ligand-induced conformational stabilization of proteins is a well-understood phenomenon in which substrates, inhibitors, cofactors, and even other proteins provide enhanced stability to proteins on binding. This phenomenon is based on the energetic coupling of the ligand-binding and protein-melting reactions. In an attempt to harness these biophysical properties for drug discovery, fully automated instrumentation was designed and implemented to perform miniaturized fluorescence-based thermal shift assays in a microplate format for the high throughput screening of compound libraries. Validation of this process and instrumentation was achieved by investigating ligand binding to more than 100 protein targets. The general applicability of the thermal shift screening strategy was found to be an important advantage because it circumvents the need to design and retool new assays with each new therapeutic target. Moreover, the miniaturized thermal shift assay methodology does not require any prior knowledge of a therapeutic target's function, making it ideally suited for the quantitative high throughput drug screening and evaluation of targets derived from genomics. 429 
INTRODUCTION

A
MAJOR CHALLENGE CURRENTLY facing conventional high throughput screening drug discovery methodologies is the ability to rapidly judge relative binding affinities for the expanding numbers of new compounds derived from combinatorial chemical libraries. Compounding this task is the recent flood of new therapeutic targets that have become available from advances in genomics-based efforts in both human and microbial organisms. Moreover, many of the targets derived from genomics have unknown functions 1, 2 and/or unknown in vivo ligands (i.e., orphan receptors), 3, 4 making conventional assay development and drug screening problematic. Therefore, it has become increasingly apparent that more general and universally applicable assays are needed in order to scale with the exponential growth of diverse compounds and targets. Some examples of general assay strategies have begun to appear in the literature, 5 many of which employ electron spray mass spectrometry as the ligand-binding detection system. 6, 7 Thermal shift assays have many biophysical attributes that satisfy the requirements of a general cross-target drug discovery assay. Ligand-induced conformational stabilization of proteins is a well-understood phenomenon in which substrates, inhibitors, cofactors, metal ions, synthetic analogs of natural ligands, and even other proteins provide enhanced stability to proteins on binding. [8] [9] [10] [11] This phenomenon is based on the energetic coupling of the ligand-binding and receptor-melting reactions, as depicted in Figure 1 . This energetic linkage results in ligand-dependent changes in the midpoint for thermally induced melting curves for the ligand-receptor complex relative to the uncomplexed receptor (⌬T m ) that are directly proportional to the ligand binding affinity (K a ). Traditionally, thermal shift assays have been conducted using differential scanning calorimeters (DSCs) that monitor the change in heat capacity as proteins undergo temperature-induced melting transitions. 8, 12 In addition, biophysical methods that employ temperature-regulated optical instrumentation that measures temperature-dependent changes in absorbance, fluorescence, and circular dichroism have also been historically used to perform thermal shift assays. [13] [14] [15] In order to exploit the nearly universal physicochemical properties of ligand-induced stabilization of proteins for applications in drug discovery, we have miniaturized the thermal shift assay for use in a high-density microplate format. The validation of this miniaturized thermal shift process, along with the implementation of the instrumentation and software, is the subject of this report.
EXPERIMENTAL PROCEDURES
Proteins
The human ␣-estrogen receptor (ESR) was purchased from PanVera (Madison, WI). Bacteriorhodopsin (H. halobium) was purchased from Sigma Chemical Co. (St. Louis, MO). Human ␣-thrombin was purchased from Enzyme Research Labs (South Bend, IN). Bovine liver dihydrofolate reductase (DHFR) was purchased from Sigma. The extracellular domains of the fibroblast growth factor receptor-1 [D(II)-D(III) FGFR-1] were cloned from a human placenta library and expressed as a secreted protein from HEK293E cells (details to be described elsewhere). The PilD enzyme, a leader peptidase and an N-methyltransferase from Pseudomonas aeruginosa, was a generous gift from Wim Hol of the University of Washington (Seattle).
Fluorescent dyes
The environmentally sensitive dyes 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS), 2,6-ANS, 2-(p-toluidinyl)-napthalene-6-sulfonic acid (2,6-TNS), and the 5-(4Љ-dimethylaminophenyl)-2-(4Ј-phenyl)oxazole family of dyes (Dapoxyl ® sulfonic acid) were purchased from Molecular Probes (Eugene, OR). Environmentally sensitive dyes are fluorophores that have low quantum yields (low QY) in solvents with high dielectric constants, such as water, but are highly fluorescent (high QY) in solvents with low dielectric constants, such as ethanol and dioxane. 16 Examples of these dyes include the napthylamine sulfonic acids such as 1,8-ANS, 2,6-ANS, and 2,6-TNS, and also the Dapoxyl family of dyes. 17 They can be used as extrinsic probes of unfolded or melted proteins because the dyes partition themselves into the melted protein or molten globule states that have low dielectric properties resembling those of organic solvents. The result is a large increase in fluorescence for the extrinsic dye as a function of protein thermal melting. These dyes are excited in the near-ultraviolet region and have emission in the visible region (460-530 nm).
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FIG. 1.
Energetics of ligand-induced conformational stabilization of proteins. The energetics of thermal shift assays is based on ligand-dependent receptor stabilization, as monitored by ⌬T m measurements for the melting transitions of ligand-receptor complexes, relative to the uncomplexed receptor. This ligand-receptor stabilization is directly related to the ligand binding affinity (⌬G bind ) because of the thermodynamic linkage between the ligand-receptor binding and ligand-receptor melting free energy functions (⌬G bind and ⌬E 1 , respectively). It is generally believed that the molten globule is the first state encountered during protein phase transitions [50] [51] [52] for most proteins, and the energetics depicted here reflect this phenomenology.
The protein-dye solutions were first dispensed into each well of a 384-well microplate (polystyrene conical-well microplates; MJ Research, Inc., Waltham, MA) in equal 2.5-or 5.0-L aliquots. Then an equal volume of test compound solution (typically 100-200 M in 5%-10% DMSO) were dispensed into each well to yield test ligands at 50-100 M in an assay volume of 5.0-10.0 L. The resulting amount of protein utilized for an average therapeutic target is 0.25-0.50 g/well (ϳ1.5 M for an ϳ30.0-kDa protein) or 100-200 g/plate, depending on the volume chosen. Finally, a small volume of mineral oil was added to each well to eliminate evaporation. Reference control wells (no test ligands), containing the appropriate amount of DMSO, were distributed on the 384-well plate, usually in rows 12 and 24. The plates were subsequently heated in the custom-designed microplate thermal shift assay instrument (Fig. 2) , which automatically monitored the complete thermal melting of the proteins through closed-circuit device (CCD) camera detection of changes in fluorescence for the extrinsic environmentally sensitive fluorophore. A Genesis 5000 liquid handling robot (Tecan Group Ltd., Männedorf, Switzerland) controlled the fluidics dispensing of all reagents to assay microplates.
RESULTS
Microplate thermal shift process and instrumentation
A fully automated miniaturized thermal shift assay that works in a high-density microplate format was designed and implemented so that 384 protein melting transitions are simultaneously processed. Pilot and beta instruments were con-
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FIG. 2. (A)
Microplate thermal shift instrumentation. The hardware employed for this study utilized a noncooled CCD imaging camera that automatically captured the fluorescence changes resulting from the extrinsic dyes that correspond to the thermal melting transitions of proteins as they were simultaneously heated on a computer-controlled heating block. Microplate heating occurred for 1-to 3-min intervals in 0.1°to 5.0°C increments for any temperature range between 25°and 99°C. The CCD images were collected at each designated time/temperature point and then stored on a personal computer for analysis at the end of the temperature range. Typically, microplate images were collected at 20-40 temperature points. Microplate well-to-well temperature uniformity was controlled to yield protein melting temperatures (T m ) with standard deviations that did not exceed Ϯ0.25°C for all 384 wells in the absence of ligands. Epiillumination from long-wavelength ultraviolet lamps provided the excitation light, and a selectable band pass filter allowed the desired fluorescence emission wavelengths to reach the CCD camera. (B) Fluorescence-based detection of thermal phase transitions in proteins.
structed to perform ϳ384 assays in ϳ1.5 h or ϳ6,000 assays/day, and are described in the legend to Figure 2A . The miniaturized thermal shift assay process begins with a purified therapeutic protein (ϳ75% pure) sample at ϳ100 g/mL in a suitable buffer near neutral pH. The protein solution is then made 100 M in an environmentally sensitive fluorescent dye and dispensed into each well of a 384-well microplate in equal 2.5-or 5.0-L aliquots. The monitoring of miniaturized thermal phase transitions was accomplished through the use of environmentally sensitive fluorescent dyes as depicted in Figure 2B . A more detailed description of the microplate thermal shift process, together with the attending hardware and software, is found in Experimental Procedures and elsewhere. [18] [19] [20] 
Validation studies
Validation of this process and the instrumentation was attempted by investigating ligand binding to more than 100 model and therapeutic target proteins. The following subset was selected from these model systems to illustrate the utility of miniaturized thermal shift assays for diverse classes of proteins.
Nuclear hormone receptors: ESR.
The nuclear hormone receptors are a superfamily of ligand-activated DNA-binding transcription factors. ESR is the prototype member of this class of receptors involved in the regulation of eucaryotic gene expression and affecting cellular proliferation and differentiation in target tissues. 21 This receptor is composed of several domains important for hormone binding, 22 DNA binding, 23 and activation of transcription.
The thermal melting transition for ESR was observed to be at 44.5°C in the absence of ligands, but was increased to 49.8°C in the presence of the known antagonist tamoxifen (Fig. 3A) . Good agreement was found for the binding affinity measurement made by the miniaturized thermal shift assay (K d ϭ 1.1 M) and that reported in the literature (IC 50 ϭ 0.42 M). 24 Often the pretransitional and posttransitional baselines (y f and y u , respectively) for the well containing the ligand do not match those for the control well. This discrepancy has three components: (1) optical effects, (2) liquid-handling variation, and (3) quenching of signal as a result of the ligand. The optical effects are derived from the limitations of using a CCD camera with epiillumination. There are optical edge effects that result from the lens of the camera, and there are optical perspective effects caused by the depth of the wells so that the fluorescence measured for wells near the middle of the plate is larger than that measured near the edges. In addition, the epi-illumination yields variable excitation light across the plate, which results in variable emission. Nonuniformity across the CCD camera chip can also contribute to the observed variability in the pre-and posttransitional baselines. The liquid-handling variation introduces small differences in volumes of reagents that result in differences in observed absolute fluorescence intensity. Also, introduction of bubbles during reagent delivery will change the absolute fluorescence intensity derived from different wells. Some degree of quenching of the fluorescence signal derived from the environmentally sensitive dyes occurs for a subset of test compounds. However, the observed variations in absolute fluorescence signal are not a problem for these miniaturized thermal shift assays because both the pre-and posttransitional baselines (y f and y u ) are measured independently for each well. Consequently, the critical thermal melting parameters, T m and ⌬H u , for each well were also determined independently within the intrawell boundaries of y f and y u (see Eqn. 3 in the Appendix).
Growth factor and cytokine receptors: FGFR-1. The FGFR-1 extracellular domains, D(II)-D(III) FGFR-1, have been shown to be important for ligand-binding interactions. [25] [26] [27] , * The known ligand pentosan polysulfate, a sulfated oligosaccharide, was found to increase the T m by 2.5°C (Fig. 3B) , which corresponds to a K d of 5.5 M at 25°C when calculated using Equation 3 (see Appendix). This is in good agreement with a reported K d of 11 M for this ligand measured using isothermal titration calorimetry. 27 Integral membrane proteins. The utility of the miniaturized thermal shift assay strategy as a drug discovery tool for the integral membrane protein class was demonstrated with the following examples.
PILD FROM PSEUDOMONAS AERUGINOSA. The enzyme PilD is a putative five-transmembrane enzyme with two catalytic activities, a leader peptidase and an N-methyltransferase activity, that are essential for the proper processing of the type IV pili proteins expressed on the surface of many gram-negative pathogens. 28, 29 The results for the miniaturized thermal shift assay of ligands binding to PilD are shown in Figure 3C . The N-methyltransferase activity cofactor S-adenosyl-L-methionine was found to increase the T m by 1.1°C, which corresponds to a binding affinity of K d ϭ 900 M. This is in good agreement with the K d of ϳ300 M previously measured using a radioactive competition assay. 30 BACTERIORHODOPSIN. The seven-transmembrane protein bacteriorhodopsin is a light-driven proton pump from bacterial purple membranes and is commonly used as a model for structure-function studies of G protein-coupled receptors (GPCRs). 31 The form of bacteriorhodopsin with retinal covalent binding to Lys 216 was reconstituted in nonionic detergents and investigated for its compatibility with the miniaturized thermal shift process. The melting transition for this receptor-ligand complex was observed to occur at 73.3°C, as shown in Figure 3D . obtained using the miniaturized thermal shift process (Fig. 4) . The seven focused libraries consisted of seven 96-well plates synthesized in sequential order. There were 213 hits out of the original 665 compounds with binding affinities that span ϳ3.5 orders of magnitude.
The results from the miniaturized thermal shift assay were found to correlate with the results obtained through the enzymatic assay as demonstrated by the reasonable fit to the slope ϭ 1.0 line for the log/log plot. The deviation of the data from a perfect fit can come from a number of sources, the first of which is the time interval (ϳ6 months) between the enzyme and thermal shift assays. Time-dependent changes for some labile ligands could account for some differences between the two methods. Another source of some of the deviation may come from the range of ligand-binding enthalpies (⌬H L ϭ 0.0 to Ϫ25.0 kcal/mol) one might expect for an assortment of different ligands binding to a given target. (For examples of compounds that have binding affinities that are entropically driven, see refs. 12 and 32.) This potential assortment for ligand-binding enthalpies translates into a range for the calculated K a (at T) for any given ligand when estimated using Equation 3 (see Appendix). For example, the use of thrombin, a ligand that yields a ⌬T m of 2.0°C, results in a calculated K a (at 37°C) of 8.5ϫ10 5 when ⌬H L ϭ 0.0 (Eqn. 3), while a ligand with ⌬H L ϭ Ϫ25.0 kcal/mol yields a calculated K a (at 37°C) of 7.1 ϫ 10 6 . Thus, in the case of thrombin, a 10-fold range in the estimated K a is possible for a given value of ⌬T m , which is consistent with the observed variation in Figure 4 . Finally, there could be a small subset of compounds that that interact with both the native and unfolded forms of thrombin, thereby resulting in smaller ⌬T m determinations (and smaller K a ) than expected if the ligand bound only to the native form of thrombin.
Data analysis for these screening experiments was simplified using a software interface that graphically displays the computed ⌬T m determinations for all 384 wells of the microplate thermal shift assay, as shown in Figure 5 . The results for one of the library plates (Plate 6) screened against thrombin is shown using an adjustable-gradient color code for ⌬T m measured for each well-the more positive the ⌬T m for an individual compound, the more deeply red-shaded the well. White signifies little or no change in T m compared with a control (T 0 ) in which no compounds are present. Thus hits can be visually identified and ranked by color and bar graph or, alternatively, they may be listed in tables that show the ⌬T m values and estimated binding affinities (K a values) for all 384 wells (not shown). More details concerning the data analysis software tools are located in the Appendix.
The software interface that graphically displays the computed PANTOLIANO ET AL. 434   FIG. 4 . Screening of focused combinatorial libraries directed at the catalytic site of human ␣-thrombin. Seven focused combinatorial libraries directed at the catalytic site of human thrombin were first assayed by a conventional enzymatic spectrophotometric assay and then compared with the results obtained using the miniaturized thermal shift process. The seven focused libraries consisted of seven 96-well plates (1 through 7) synthesized in sequential order: red diamonds ϭ plate 1; blue boxes ϭ plate 2; magenta boxes ϭ plate 3; cyan triangles ϭ plate 4; brown circles ϭ plate 5; green diamonds ϭ plate 6; black triangles ϭ plate 7. The results were plotted in a log/log format for direct comparison of the extent to which the two different assay measurements are consistent. The solid line of slope 1.0 represents a perfect match for the two methods of analysis. Thrombin was present at 1.0 M in 50 mM Hepes (pH 7.5) and 0.1 M NaCl, and the Dapoxyl sulfonic acid was present at 100 M. Excitation of the fluorophore was effected using a long-wavelength ultraviolet lamp, and the emission was filtered through a band-pass filter that allowed 500-to 530-nm wavelength light to pass to the CCD camera. The compounds from the focused libraries were present at a final concentration of ϳ17 M.
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FIG. 5.
Data analysis software tools. The ⌬T m data analysis for one of the seven compound library plates, plate 6, screened against human thrombin (Fig. 4) is shown in various levels of detail. The software used to analyze the miniaturized thermal shift assays performed in 384-well plates displays the ⌬T m values as an adjustable-gradient color code, shown at the right of the simulated 384-well plate. The more red the well, the more positive the ⌬T m . Similarly, the more blue the well, the more negative the ⌬T m . White signifies little or no change in T m compared with control (T 0 ). The original 96-well plate of compounds was replicated four times on the 384-well assay plate in a quad format to reveal the level of reproducibility of these measurements (A1, A13, I1, and I13 have the identical compound). The control wells, which contain only DMSO, are designated as green, which for this plate are wells H12, H24, P12, and P24. The fluorescence intensity versus temperature data for any well can be displayed for demonstration purposes by double clicking on any well. An example is shown at the right for well M23, which is compared with the data for a control P12. This compound shows a ⌬T m of 4.3°C and is one of the 21 hits on this plate with ⌬T m 0.5°C. A three-dimensional bar chart representation of the ⌬T m data for this plate is also shown at the bottom. The software was written in Cϩϩ and runs on all Microsoft Windows™-based platforms.
⌬T m determinations for all 384 wells of the microplate thermal shift assay is described in the legend to Figure 5 .
Multiligand binding events.
A demonstration of the effects of multiligand binding events on the miniaturized thermal shift assay appears in Table 1 . Binding of the coenzyme NADP ϩ and the folate mimetic methotrexate (MTX) to the bovine liver enzyme DHFR was analyzed individually as well as together. Alone, the individual ligands produced ⌬T m values of 6.3°C for NADP ϩ and 7.7°C for MTX, which correspond to binding affinities of K d ϭ 2.4 M for NADP ϩ and 5.8 nM for MTX (at 25°C), when calculated using Equation 3. The measurement for MTX is in agreement with those appearing in the literature (see Table 1 ). Importantly, when both ligands are present together, there is a much larger increase in ⌬T m of 18.1°C, indicating that the ligand-induced stabilization is to some extent additive, although the observed shift is 4.1°C larger than that expected for the simple sum of the ⌬T m values for the individual ligands. This deviation from perfect additivity suggests some positive cooperativity for these two ligands binding at adjacent sites. Support for this supposition comes from the structural and functional evidence for positive cooperativity of the binding of these two ligands at adjacent sites in DHFR enzymes from both eukaryotic and prokaryotic organisms. [33] [34] [35] For example, a 100-fold increase in binding affinity of MTX (at 10°C) was reported when NADPH was bound to the bovine liver DHFR 36 (see Table 1 ).
DISCUSSION
General drug discovery applications
The successful measurements of binding affinity for assorted ligands binding to diverse classes of protein targets (Figs. 3 and  4) demonstrate that the miniaturized thermal shift assay strategy has wide cross-target utility. Of the ϳ100 protein-ligand complexes investigated to date, only proteins with heme groups were observed to yield low fluorescence as a result of quenching of the extrinsic dye fluorescence signal, although this did not preclude using the assay at a higher concentration.
The binding affinity results obtained for the miniaturized thermal shift assay were found to be largely consistent with the results obtained through enzymatic, radioactive, fluorescence polarization, isothermal titration calorimetry, or other kinds of assays. This was best demonstrated by the correlation between the continuous spectrometric enzyme assay and thermal shift data for the combinatorial libraries directed at the catalytic site of thrombin (Fig. 4) .
One advantage of the miniaturized thermal shift strategy is the fundamental biophysical basis of the assay, which circumvents the need to design and retool new assays for each new protein target. Another related outcome is that this strategy does not require any prior knowledge of a specific therapeutic target's function in order to screen libraries and optimize drug leads. In this regard, the results for bacteriorhodopsin and the estrogen receptor suggest that the miniaturized thermal shift assay strategy will be useful for drug discovery efforts with GPCRs and nuclear hormone receptors, especially those orphan receptors for which drug screening presents a problem because of the lack of known ligands. These properties make a miniaturized thermal shift assay strategy ideally suited for high throughput drug screening and evaluation of targets derived from genomics.
Multiligand binding applications
The data in Table 1 illustrate the utility of the miniaturized thermal shift assay for assessing multiligand binding to protein targets. The data show that this process can not only identify ligands binding to substrate binding sites of enzymes, but also identify and judge the cooperativity of ligands binding to cofactor, allosteric, and/or regulatory sites on therapeutic targets. Exosites on enzymes are often useful targets of therapeutic intervention, as demonstrated by the thrombin cofactor heparin, an effective anticoagulant. 37, 38 In this regard, the miniaturized thermal shift assay could be used in conjunction with protein structural information (nuclear magnetic resonance [NMR] or x-ray diffraction), and be used to identify ligands binding at ad- jacent sites (Table 1) . In this application, the thermal shift assay may serve as an ideal source of information for structurebased drug design approaches such as the "SAR by NMR" approach first described by Shuker et al. 39 The assessment of multiligand binding interactions illustrates an advantage that a thermal shift assay has over other assays that are often limited to a single binding site on a protein. The universal nature of the thermal assay extends to all potential ligand binding sites over the entire surface (and volume) of a protein molecule. Moreover, cooperativity (positive or negative) for ligand binding is quickly determined by the deviation from additivity for the ⌬T m measurements (see Table 1) , and all at a single ligand concentration in a single well. Similarly, by eliminating the necessity for dose ranging of the ligand concentration, the thermal shift assay leads to a large dynamic range for assessing ligand binding affinity using a single ligand concentration. 8 Indeed, the results for ligand binding to thrombin (Fig. 4) illustrate that 3.5 orders of magnitude in binding affinity, corresponding to a ⌬T m range of 0.5°to ϳ10.0°C, can be assessed at a single ligand concentration (17 M) and in single respective wells.
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High throughput screening technical issues
Some technical issues that were observed while performing high throughput screening of large compound libraries (ϳ100,000) included occasional fluorescence quenching of the extrinsic dyes by a small subset of library compounds. This can be minimized by adjusting the concentration of compounds to be screened so that they are ϳ25 M or lower. This screening concentration will obviate the identification of hits with K d greater than ϳ12 M, but many of these weaker hits are often ignored anyway when more potent hits are present.
Another issue that was observed on occasion is related to the multiligand binding phenomenon discussed above. Compounds that can bind to more than one site on a protein will appear more potent because of the additivity of the ⌬T m values for the respective binding sites. Although this can be useful information, especially in the context of structure-based drug design, it can bias a structure-activity relationship analysis of hits. Dose ranging of initial hits can help to identify these multisite ligands because of the larger dependence of ⌬T m on the concentration of ligand expected for these compounds (see Eqn. 2 in Appendix). We also have employed isothermal titrating calorimetry 40 to obtain stoichiometry measurements for compounds with unusually large ⌬T m values.
The hit validation process for "positives" that come out of miniaturized thermal shift assay primary screens starts off very similar to those from other HTS assays in that families of compounds with different chemical scaffolds are chosen for dose ranging to estimate potency. However, because binding enthalpy can be different for different compound classes, some variability is introduced into the calculations for the apparent K d for individual compounds. Thus, in the absence of any other secondary assay, it is necessary to give all classes even weight when it comes to potency until other properties and characteristics (i.e., liquid chromatography-mass spectrometry quality control) take their toll in winnowing down the number of classes of compounds still considered valid hits.
Carrying three or more classes of compounds through hit validation programs is not uncommon anyway. For example, at many pharmaceutical companies, testing purified solids is often a point at which positives drop out of consideration because of the decay of compounds in liquid DMSO stocks, resulting in false positives (in any assay). Moreover, at the point at which one has purified solids, it is also possible to employ isothermal titration calorimetry to directly measure binding enthalpy and K d for a few members of each lead series and reevaluate potency.
Finally, further improvements in liquid handling and instrumentation will enable additional miniaturization of the thermal shift assay to 1.0-L and lower volumes, which will greatly reduce the amount of protein required per well (assay).
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